REFERENCES
1. World Health Organization. Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [Last accessed on 7 June 2023].
2. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021;28:1682-90.
3. Malik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure. StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430873/ [Last accessed on 7 June 2023].
4. Dewey CM, Spitler KM, Ponce JM, Hall DD, Grueter CE. Cardiac-secreted factors as peripheral metabolic regulators and potential disease biomarkers. J Am Heart Assoc 2016;5:e003101.
6. Schulte C, Westermann D, Blankenberg S, Zeller T. Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol 2015;7:843-60.
7. Stastna M, Van Eyk JE. Investigating the secretome: lessons about the cells that comprise the heart. Circ Cardiovasc Genet 2012;5:o8-18.
8. Blackwood EA, Thuerauf DJ, Stastna M, et al. Proteomic analysis of the cardiac myocyte secretome reveals extracellular protective functions for the ER stress response. J Mol Cell Cardiol 2020;143:132-44.
9. Harouki N, Nicol L, Remy-Jouet I, et al. The IL-1β antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. JACC Basic Transl Sci 2017;2:418-30.
10. Schumacher SM, Naga Prasad SV. Tumor necrosis factor-α in heart failure: an updated review. Curr Cardiol Rep 2018;20:117.
11. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016;106:62-9.
12. Cox EJ, Marsh SA. A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PLoS One 2014;9:e92903.
13. Jeffrey DA, Pires Da Silva J, Garcia AM, et al. Serum circulating proteins from pediatric patients with dilated cardiomyopathy cause pathologic remodeling and cardiomyocyte stiffness. JCI Insight 2021;6:e148637.
14. Liu Z, Ni J, Li L, et al. SERCA2a: a key protein in the Ca2+ cycle of the heart failure. Heart Fail Rev 2020;25:523-35.
15. Vigil-Garcia M, Demkes CJ, Eding JEC, et al. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling. Cardiovasc Res 2021;117:1532-45.
16. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923-31.
17. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007;12:331-43.
18. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation 2012;126:e327-32.
19. Vassiliadis E, Barascuk N, Didangelos A, Karsdal MA. Novel cardiac-specific biomarkers and the cardiovascular continuum. Biomark Insights 2012;7:45-57.
20. Xu D, Di K, Fan B, et al. MicroRNAs in extracellular vesicles: Sorting mechanisms, diagnostic value, isolation, and detection technology. Front Bioeng Biotechnol 2022;10:948959.
21. Garcia-Martin R, Wang G, Brandão BB, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature 2022;601:446-51.
22. Albanese M, Chen YA, Hüls C, et al. MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genet 2021;17:e1009951.
23. Robert AW, Pereira IT, Dallagiovanna B, Stimamiglio MA. Secretome analysis performed during in vitro cardiac differentiation: discovering the cardiac microenvironment. Front Cell Dev Biol 2020;8:49.
24. Srivastava H, Pozzoli M, Lau E. Defining the roles of cardiokines in human aging and age-associated diseases. Front Aging 2022;3:884321.
25. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
26. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
27. Ichiki T, Burnett JC Jr. A new signal from B-type natriuretic peptide in ST-elevation myocardial infarction: what does it mean for B-type natriuretic peptide and innovative diagnostics? Circulation 2010;122:229-32.
28. George J, Struthers AD. Chapter 31 - Natriuretic peptides. In: Comprehensive hypertension. Amsterdam: Elsevier 2007. pp. 349-62.
29. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci 2019;20:1820.
30. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92:843-9.
31. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;191:341-66.
32. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-407.
33. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 2009;55:53-60.
34. Siriwardena M, Kleffmann T, Ruygrok P, et al. B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation 2010;122:255-64.
35. Seidelmann SB, Vardeny O, Claggett B, et al. An NPPB promoter polymorphism associated with elevated N-terminal pro-B-type natriuretic peptide and lower blood pressure, hypertension, and mortality. J Am Heart Assoc 2017;6:e005257.
36. Sangaralingham SJ, Kuhn M, Cannone V, Chen HH, Burnett JC. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovasc Res 2023;118:3416-33.
37. Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001;51:489-94.
38. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr. Atrial natriuretic peptide in heart failure. J Am Coll Cardiol 1993;22:86A-92A.
39. Tanajak P, Chattipakorn SC, Chattipakorn N. Effects of fibroblast growth factor 21 on the heart. J Endocrinol 2015;227:R13-30.
40. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53.
41. Keinicke H, Sun G, Mentzel CMJ, et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. Endocr Connect 2020;9:755-68.
42. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018-27.
43. Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun 2015;459:124-30.
44. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013;4:2019.
45. Tao J, Wei X, Huang Y, et al. Sfrp1 protects against acute myocardial ischemia (AMI) injury in aged mice by inhibiting the Wnt/β-catenin signaling pathway. J Cardiothorac Surg 2021;16:12.
46. Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep 2013;3:2767.
47. Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: a meta-analysis. Front Endocrinol 2023;14:1108234.
48. Wu G, Wu S, Yan J, et al. Fibroblast growth factor 21 predicts short-term prognosis in patients with acute heart failure: a prospective cohort study. Front Cardiovasc Med 2022;9:834967.
49. Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail 2022;15:e008910.
50. Poniatowski ŁA, Wojdasiewicz P, Gasik R, Szukiewicz D. Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediators Inflamm 2015;2015:137823.
51. Rochette L, Dogon G, Zeller M, Cottin Y, Vergely C. GDF15 and cardiac cells: current concepts and new insights. Int J Mol Sci 2021;22:8889.
52. Wang J, Wei L, Yang X, Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc 2019;8:e012826.
53. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017;63:140-51.
54. Rochette L, Zeller M, Cottin Y, Vergely C. Insights into mechanisms of gdf15 and receptor gfral: therapeutic targets. Trends Endocrinol Metab 2020;31:939-51.
55. Li M, Duan L, Cai YL, et al. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol 2020;19:120.
56. Chang JY, Hong HJ, Kang SG, Kim JT, Zhang BY, Shong M. The role of growth differentiation factor 15 in energy metabolism. Diabetes Metab J 2020;44:363-71.
57. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013;153:828-39.
58. Chen L, Luo G, Liu Y, et al. Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity. Cell Death Dis 2021;12:665.
59. Olson KA, Beatty AL, Heidecker B, et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts. Eur Heart J 2015;36:3426-34.
60. Wells L, Edwards KA, Bernstein SI. Myosin heavy chain isoforms regulate muscle function but not myofibril assembly. EMBO J 1996;15:4454-9.
61. Gollapudi S, Michael J, Chandra M. Striated muscle dynamics. In: Reference module in biomedical sciences. Amsterdam: Elsevier: 2014.
62. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997;100:2362-70.
63. Léger JO, Larue C, Ming T, et al. Assay of serum cardiac myosin heavy chain fragments in patients with acute myocardial infarction: determination of infarct size and long-term follow-up. Am Heart J 1990;120:781-90.
64. Löfberg M, Tähtelä R, Härkönen M, Somer H. Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis. Diagnostic specificity of new biochemical markers. Arch Neurol 1995;52:1210-4.
65. Biering-Sørensen T, Minamisawa M, Claggett B, et al. Cardiac myosin activator omecamtiv mecarbil improves left ventricular myocardial deformation in chronic heart failure: The COSMIC-HF trial. Circ Heart Fail 2020;13:e008007.
66. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018;9:754.
67. Sun H, Koike T, Ichikawa T, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 2005;167:1139-48.
68. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
69. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996;156:4815-20.
70. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
71. Joshi MS, Tong L, Cook AC, et al. Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival. Cardiovasc Pathol 2012;21:428-35.
72. Sheikh AS, Yahya S, Sheikh NS, Sheikh AA. C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome. Heart Views 2012;13:7-12.
73. Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc Res 2021;117:2326-39.
75. Collinson PO, Boa FG, Gaze DC. Measurement of cardiac troponins. Ann Clin Biochem 2001;38:423-49.
76. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 2005;66:12-21.
77. Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002;113:717-22.
78. Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochim Biophys Acta Biomembr 2010;1799:114-8.
79. Pellegrini L, Foglio E, Pontemezzo E, Germani A, Russo MA, Limana F. HMGB1 and repair: focus on the heart. Pharmacol Ther 2019;196:160-82.
80. Zhang C, Mo M, Ding W, et al. High-mobility group box 1 (HMGB1) impaired cardiac excitation-contraction coupling by enhancing the sarcoplasmic reticulum (SR) Ca2+ leak through TLR4-ROS signaling in cardiomyocytes. J Mol Cell Cardiol 2014;74:260-73.
81. Wahid A, Chen W, Wang X, Tang X. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomed Pharmacother 2021;139:111555.
82. Kohno T, Anzai T, Naito K, et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009;81:565-73.
83. Yu P, Liu M, Zhang B, et al. Cardiomyocyte-restricted high-mobility group box 1 (HMGB1) deletion leads to small heart and glycolipid metabolic disorder through GR/PGC-1α signalling. Cell Death Discov 2020;6:106.
84. Raucci A, Di Maggio S, Scavello F, D'Ambrosio A, Bianchi ME, Capogrossi MC. The Janus face of HMGB1 in heart disease: a necessary update. Cell Mol Life Sci 2019;76:211-29.
85. Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-26.
86. Li W, Sama AE, Wang H. Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 2006;6:130-5.
87. Liang CJ, Wang ZW, Chang YW, Lee KC, Lin WH, Lee JL. SFRPs Are biphasic modulators of Wnt-signaling-elicited cancer stem cell properties beyond extracellular control. Cell Rep 2019;28:1511-25.e5.
88. Surana R, Sikka S, Cai W, et al. Secreted frizzled related proteins: implications in cancers. Biochim Biophys Acta 2014;1845:53-65.
89. Gay A, Towler DA. Wnt signaling in cardiovascular disease: opportunities and challenges. Curr Opin Lipidol 2017;28:387-96.
90. Pan S, Zhao X, Wang X, et al. Sfrp1 attenuates TAC-induced cardiac dysfunction by inhibiting Wnt signaling pathway- mediated myocardial apoptosis in mice. Lipids Health Dis 2018;17:202.
91. Huang A, Huang Y. Role of Sfrps in cardiovascular disease. Ther Adv Chronic Dis 2020;11:2040622320901990.
92. Sklepkiewicz P, Shiomi T, Kaur R, et al. Loss of secreted frizzled-related protein-1 leads to deterioration of cardiac function in mice and plays a role in human cardiomyopathy. Circ Heart Fail 2015;8:362-72.
93. Hao K, Lei W, Wu H, et al. LncRNA-Safe contributes to cardiac fibrosis through Safe-Sfrp2-HuR complex in mouse myocardial infarction. Theranostics 2019;9:7282-97.
94. Wei WY, Zhao Q, Zhang WZ, et al. Secreted frizzled-related protein 2 prevents pressure-overload-induced cardiac hypertrophy by targeting the Wnt/β-catenin pathway. Mol Cell Biochem 2020;472:241-51.
95. Vatner DE, Oydanich M, Zhang J, Babici D, Vatner SF. Secreted frizzled-related protein 2, a novel mechanism to induce myocardial ischemic protection through angiogenesis. Basic Res Cardiol 2020;115:48.
96. Zhang Z, Deb A, Zhang Z, et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2009;46:370-7.
97. Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA 2007;104:1643-8.
98. Barandon L, Dufourcq P, Costet P, et al. Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res 2005;96:1299-306.
99. Vigneron F, Dos Santos P, Lemoine S, et al. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res 2011;90:49-56.
100. Hsueh YC, Hodgkinson CP, Gomez JA. The role of Sfrp and DKK proteins in cardiomyocyte development. Physiol Rep 2021;9:e14678.
101. Ress C, Paulweber M, Goebel G, et al. Circulating Wnt inhibitory factor 1 levels are associated with development of cardiovascular disease. Atherosclerosis 2018;273:1-7.
102. Cao M, Wang H, Li W, et al. Inverse Associations between circulating secreted frizzled related protein 2 (sFRP2) and cardiometabolic risk factors. Front Cardiovasc Med 2021;8:723205.
103. Nakamoto M, Matsubara S, Miyauchi T, Obama H, Ozawa M, Muramatsu T. A new family of heparin binding growth/differentiation factors: differential expression of the midkine (MK) and HB-GAM genes during mouse development. J Biol Chem 1992;112:346-9.
104. Mitsiadis TA, Salmivirta M, Muramatsu T, et al. Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development 1995;121:37-51.
105. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:410-25.
106. Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene 2020;39:2040-54.
107. Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol 2014;171:2925-39.
108. Nakamura E, Kadomatsu K, Yuasa S, et al. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 1998;3:811-2.
110. Kitahara T, Shishido T, Suzuki S, et al. Serum midkine as a predictor of cardiac events in patients with chronic heart failure. J Card Fail 2010;16:308-13.
111. Guzel S, S Cinemre FB, Guzel EC, et al. Midkine levels and its relationship with atherosclerotic risk factors in essential hypertensive patients. Niger J Clin Pract 2018;21:894-900.
112. Takemoto Y, Horiba M, Harada M, et al. Midkine promotes atherosclerotic plaque formation through its pro-inflammatory, angiogenic and anti-apoptotic functions in apolipoprotein e-knockout mice. Circ J 2017;82:19-27.
113. Ishiguro H, Horiba M, Takenaka H, et al. A single intracoronary injection of midkine reduces ischemia/reperfusion injury in swine hearts: a novel therapeutic approach for acute coronary syndrome. Front Physiol 2011;2:27.
114. Barnett CF, De Marco I. 59 - Pulmonary hypertension due to lung disease. In: Murray and Nadel's textbook of respiratory medicine, 6th ed. 2016. pp. 1050-65.e5.
115. Bupha-Intr T, Haizlip KM, Janssen PM. Role of endothelin in the induction of cardiac hypertrophy in vitro. PLoS One 2012;7:e43179.
116. Archer CR, Robinson EL, Drawnel FM, Roderick HL. Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cell Signal 2017;36:240-54.
117. National Library of Medicine. ECE1 endothelin converting enzyme 1 [Homo sapiens (human)] - Gene - NCBI. Available from: https://www.ncbi.nlm.nih.gov/gene/1889 [Last accessed on 7 June 2023].
118. Aalto K, Autio A, Kiss EA, et al. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 2011;118:3725-33.
119. Lin CH, Yeh YC, Yang KD. Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers. J Formos Med Assoc 2021;120:5-24.
120. Ito T, Ishigami M, Matsushita Y, et al. Secreted ectodomain of SIGLEC-9 and MCP-1 synergistically improve acute liver failure in rats by altering macrophage polarity. Sci Rep 2017;7:44043.
121. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-66.
122. Nigam PK, Narain VS, Kumar A. Sialic acid in cardiovascular diseases. Indian J Clin Biochem 2006;21:54-61.
123. Nicoll G, Ni J, Liu D, et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 1999;274:34089-95.
124. Von Gunten S, Yousefi S, Seitz M, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005;106:1423-31.
125. Schaub A, Von Gunten S, Vogel M, et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 2011;66:1030-7.
126. Kim B, Lee KJ. Activation of Nm23-H1 to suppress breast cancer metastasis via redox regulation. Exp Mol Med 2021;53:346-57.
127. Mátyási B, Farkas Z, Kopper L, et al. The Function of NM23-H1/NME1 and Its Homologs in Major Processes Linked to Metastasis. Pathol Oncol Res 2020;26:49-61.
128. Zhou Y, Artman M. Nucleoside diphosphate kinase: a new player in heart failure? Cardiovasc Res 2001;49:7-10.
129. Abu-Taha IH, Heijman J, Hippe HJ, et al. Nucleoside diphosphate kinase-C suppresses cAMP formation in human heart failure. Circulation 2017;135:881-97.
130. Lutz S, Mura RA, Hippe HJ, Tiefenbacher C, Niroomand F. Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by beta-adrenergic signaling. Br J Pharmacol 2003;140:1019-26.
131. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Thrombospondins: a role in cardiovascular disease. Int J Mol Sci 2017;18:1540.
132. Frolova EG, Sopko N, Blech L, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J 2012;26:2363-73.
133. Cingolani OH, Kirk JA, Seo K, et al. Thrombospondin-4 is required for stretch-mediated contractility augmentation in cardiac muscle. Circ Res 2011;109:1410-4.
134. Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin-1 and thrombospondin-2 in cardiovascular diseases (Review). Int J Mol Med 2020;45:1275-93.
135. Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004;95:515-22.
136. Befekadu R, Christiansen K, Larsson A, Grenegård M. Increased plasma cathepsin S and trombospondin-1 in patients with acute ST-segment elevation myocardial infarction. Cardiol J 2019;26:385-93.
137. Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: potential functions in cardiac remodeling. J Cell Commun Signal 2009;3:201-13.
138. Gonzalez-Quesada C, Cavalera M, Biernacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res 2013;113:1331-44.
139. Lee CH, Seto WK, Lui DT, et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care 2021;44:2089-97.
140. Kaiser R, Frantz C, Bals R, Wilkens H. The role of circulating thrombospondin-1 in patients with precapillary pulmonary hypertension. Respir Res 2016;17:96.
141. Lee C, Wu M, Lui D, et al. Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovasc Diabetol 2022;21:231.
143. Besse S, Nadaud S, Balse E, Pavoine C. Early protective role of inflammation in cardiac remodeling and heart failure: focus on TNFα and resident macrophages. Cells 2022;11:1249.
144. Feng Y, Chao W. Toll-like receptors and myocardial inflammation. Int J Inflam 2011;2011:170352.
145. Lafuse WP, Wozniak DJ, Rajaram MVS. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. Cells 2020;10:51.
146. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014;11:255-65.
147. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995;96:1042-52.
148. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015;116:1254-68.
149. Liu L, Yang X, Chen X, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 2012;39:2683-8.
150. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
151. Jung M, Ma Y, Iyer RP, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol 2017;112:33.
152. Zhou SS, Jin JP, Wang JQ, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 2018;39:1073-84.
153. Dirkx E, da Costa Martins PA, De Windt LJ. Regulation of fetal gene expression in heart failure. Biochim Biophys Acta 2013;1832:2414-24.
154. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018;9:402.
155. Jang JH, Lee TJ. The role of microRNAs in cell death pathways. Yeungnam Univ J Med 2021;38:107-17.
156. Wang J, Liew OW, Richards AM, Chen YT. Overview of microRNAs in cardiac hypertrophy, fibrosis, and apoptosis. Int J Mol Sci 2016;17:749.
157. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci USA 2005;102:18986-91.
158. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-17.
159. Port JD, Walker LA, Polk J, Nunley K, buttrick PM, sucharov CC. Temporal expression of miRNAs and mRNAs in a mouse model of myocardial infarction. Physiol Genomics 2011;43:1087-95.
160. Liu X, Meng H, Jiang C, Yang S, Cui F, Yang P. Differential microRNA expression and regulation in the rat model of post-infarction heart failure. PLoS One 2016;11:e0160920.
161. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-24.
162. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-54.
163. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010;106:166-75.
164. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008;45:185-92.
165. Peterlin A, Počivavšek K, Petrovič D, Peterlin B. The role of microRNAs in heart failure: a systematic review. Front Cardiovasc Med 2020;7:161.
166. Shen NN, Wang JL, Fu YP. The microRNA expression profiling in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:856358.
167. Sucharov CC, Kao DP, Port JD, et al. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight 2017;2:e89169.
168. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
169. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-99.
170. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679.
171. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402-7.
172. Mi S, Zhang J, Zhang W, Huang RS. Circulating microRNAs as biomarkers for inflammatory diseases. Microrna 2013;2:63-71.
173. Vavassori C, Cipriani E, Colombo GI. Circulating microRNAs as novel biomarkers in risk assessment and prognosis of coronary artery disease. Eur Cardiol 2022;17:e06.
174. Sucharov CC, Miyamoto SD, Garcia AM. Circulating microRNAs as biomarkers in pediatric heart diseases. Prog Pediatr Cardiol 2018;49:50-2.
175. He X, Ji J, Wang T, Wang MB, Chen XL. Upregulation of Circulating miR-195-3p in Heart Failure. Cardiology 2017;138:107-14.
176. McManus DD, Ambros V. Circulating MicroRNAs in cardiovascular disease. Circulation 2011;124:1908-10.
177. Ewelina K, Eljaszewicz A, Kazimierczyk R, et al. Altered microRNA dynamics in acute coronary syndrome. Postep Kardiol Inter 2020;16:287-93.
178. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011;51:872-5.
179. Bye A, Røsjø H, Nauman J, et al. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals - The HUNT study. J Mol Cell Cardiol 2016;97:162-8.
180. Kukreja RC, Yin C, Salloum FN. MicroRNAs: new players in cardiac injury and protection. Mol Pharmacol 2011;80:558-64.
181. Aonuma T, Moukette B, Kawaguchi S, et al. Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A. JCI Insight 2021;6:e150405.
182. Liu B, Wei H, Lan M, Jia N, Liu J, Zhang M. MicroRNA-21 mediates the protective effects of salidroside against hypoxia/reoxygenation-induced myocardial oxidative stress and inflammatory response. Exp Ther Med 2020;19:1655-64.
183. Yin C, Wang X, Kukreja RC. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice. FEBS Lett 2008;582:4137-42.
184. Gao S, Gao H, Dai L, et al. miR-126 regulates angiogenesis in myocardial ischemia by targeting HIF-1α. Exp Cell Res 2021;409:112925.
187. Crimmins EM. Lifespan and healthspan: past, present, and promise. Gerontologist 2015;55:901-11.
188. Yoshida Y, Nakanishi K, Daimon M, et al. Alteration of cardiac performance and serum B-type natriuretic peptide level in healthy aging. J Am Coll Cardiol 2019;74:1789-800.
189. Schafer MJ, Zhang X, Kumar A, et al. The senescence-associated secretome as an indicator of age and medical risk. JCI Insight 2020;5:133668.
190. Madonna R. Cellular aging and rejuvenation in ischemic heart disease: a translation from basic science to clinical therapy. J Cardiovasc Aging 2022;2:12.
191. Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg 2018;7:31-55.
192. Almond CSD, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation 2009;119:717-27.
193. Lipshultz SE, Law YM, Asante-Korang A, et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American heart association. Circulation 2019;140:e9-68.
194. Broch K, Murbræch K, Andreassen AK, Hopp E, Aakhus S, Gullestad L. Contemporary outcome in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2015;116:952-9.
